Thus, our study thereby provides a rationale for the use of PRATA or selective PRATD to control clinical essential hypertension, especially for patients who have reduced plasma CGRP or are resistant to conventional BP-lowing medicines (Fig. 7). The gene discussed is CALCA; the disease is essential hypertension.